3-(3,4-dichlorophenyl)oxazolidin-2-one | 90273-45-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3,4-dichlorophenyl)oxazolidin-2-one
• 英文别名: 3-(3,4-Dichlorophenyl)-1,3-oxazolidin-2-one
• CAS: 90273-45-3
• 化学式: C₉H₇Cl₂NO₂
• 分子量: 232.066
• InChiKey: PKBAGPKKXQCCBT-UHFFFAOYSA-N

物化性质

• 沸点：
  350.5±35.0 °C(Predicted)
• 密度：
  1.493±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(3,4-dichlorophenyl)oxazolidin-2-one 、 6-氯-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚 以 二甲基亚砜 为溶剂， 反应 16.0h， 以22%的产率得到3,4-dichloro-N-(2-(6-chloro-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)ethyl)aniline
  参考文献：
  名称：

  WO2020037155A5

  摘要：

  公开号：

  WO2020037155A5
• 作为产物：
  描述：

  1-chloro-2-(3,4-dichloro-phenylcarbamoyloxy)-ethane 在 sodium hydroxide 作用下， 生成 3-(3,4-dichlorophenyl)oxazolidin-2-one
  参考文献：
  名称：

  The Preparation of 2-Imidazolones. A Novel Ring Closure of Propynylureas with Phosphorus Pentachloride

  摘要：

  DOI：

  10.1021/jo01056a022

文献信息

• Synthesis of N-aryl-2-oxazolidinones from cyclic carbonates and aromatic amines catalyzed by bio-catalyst
  作者：Congmin Mei、Yibo Zhao、Ke Zou、Changsheng Cao、Guangsheng Pang、Yanhui Shi

  DOI：10.1007/s11164-017-3222-y

  日期：2018.3

  A convenient and effective method of synthesizing 3-aryl-2-oxazolidinones from cyclic carbonates and aryl amines catalyzed by bio-catalyst adenine in the presence of Et3N under solvent-free conditions is described. The protocol is suitable for the wide scope of substrates, e.g. cyclic carbonates with or without substitutes, and aryl amines with either electron-withdrawing or electron-donating group

  描述了在无溶剂条件下在Et 3 N存在下由生物催化剂腺嘌呤催化的环状碳酸酯和芳基胺合成3-芳基-2-恶唑烷酮的便捷有效方法。该方案适用于多种底物，例如带或不带取代基的环状碳酸酯，以及具有吸电子或供电子基团的芳基胺。即使在位阻情况下，在最佳条件下也能以良好或优异的收率获得产品。研究了反应时间，温度，催化剂用量和原料用量对反应的影响，并探讨了反应机理。
• A straightforward one-pot synthesis of bioactive N-aryl oxazolidin-2-ones via a highly efficient Fe₃O₄@SiO₂-supported acetate-based butylimidazolium ionic liquid nanocatalyst under metal- and solvent-free conditions
  作者：Radhika Gupta、Manavi Yadav、Rashmi Gaur、Gunjan Arora、Rakesh Kumar Sharma

  DOI：10.1039/c7gc01414g

  日期：——

  A supported ionic liquid-based magnetic nanocatalyst has been fabricated for the formation of pharmaceutically important N-aryl oxazolidin-2-ones.

  已制备一种支持的离子液体基磁性纳米催化剂，用于合成具有药用重要性的N-芳基噁唑烷-2-酮。
• New N- and O-arylations with phenylboronic acids and cupric acetate
  作者：Dominic M.T Chan、Kevin L Monaco、Ru-Ping Wang、Michael P Winters

  DOI：10.1016/s0040-4039(98)00503-6

  日期：1998.5

  compounds at room temperature with phenylboronic acids and cupric acetate in the presence of a tertiary amine promoter is described. Substrates include phenols, amines, anilines, amides, imides, ureas, carbamates, and sulfonamides.

  描述了一种在叔胺促进剂存在下在室温下用苯基硼酸和乙酸铜使含NH和OH的化合物芳基化的新方法。底物包括苯酚，胺，苯胺，酰胺，酰亚胺，脲，氨基甲酸酯和磺酰胺。
• Ruthenium(II)-Catalyzed C–H Functionalization Using the Oxazolidinone Heterocycle as a Weakly Coordinating Directing Group: Experimental and Computational Insights
  作者：Jamie A. Leitch、Philippe B. Wilson、Claire L. McMullin、Mary F. Mahon、Yunas Bhonoah、Ian H. Williams、Christopher G. Frost

  DOI：10.1021/acscatal.6b01370

  日期：2016.8.5

  Herein, we report the ruthenium-catalyzed ortho C-H alkenylation of a wide range of N-aryloxazolidinone scaffolds. Alkenylation was achieved with complete mono selectivity with a scope of 27 examples in 2-MeTHF. Yields ranged from 23 to 94%, producing highly decorated oxazolidinone scaffolds. A kinetically relevant C-H cleavage was also observed with a kinetic isotope effect (KIE) of similar to 2. Density functional theory calculations provided information about mechanism, detailing the beta-hydride elimination as the most energetically challenging step of 13.5 kcal mol(-1). In-depth computational kinetic studies also predicted a KIE of 2.17 for C-H cleavage and an intrinsic KIE for the reaction of 2.22, in line with the experimentally observed value.
• 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF
  申请人：Recreo Pharmaceuticals Inc.

  公开号：EP3836919A1

  公开（公告）日：2021-06-23